| LIFESTYLE MANAGEMENT |
The EFPIA Analytical Lifecycle Management Team
The authors examine key questions and answers about various aspects relating to the enhanced approach for analytical procedure lifecycle management.
read more
| TECHNOLOGY TRANSFER |
Agnes Shanley
Tech transfer is evolving into close collaboration and communication, as potential problems are considered sooner and new technology is applied. read more
| TRAINING AND SOPS |
Kent Malmros
Simplified role-based training can lead to better quality metrics and compliance.
read more
| RISK ASSESSMENT |
Sharon Ayd
GMP non-compliance can spill over and impact patient access to life-saving medications. read more
| API SYNTHESIS & MANUFACTURING |
Cynthia A. Challener
Antibody-based drugs offer new mechanisms of action and greater specificity.
read more
| COMBINATION PRODUCTS |
Jennifer Markarian
Using training devices may ease patient anxiety about using autoinjectors and prefilled syringes, potentially leading to improved patient adherence.
read more
| TRANSDERMAL DRUG MANUFACTURING |
Jennifer Markarian
Drug and adhesive formulation are crucial to the development of microneedle patches for pharmaceutical transdermal delivery systems.
read more
| SCALE UP |
Jennifer Markarian
Boehringer Ingelheim plans to develop and test new strategies at its Solids Launch facility.
read more
| BIOBURDEN CONTROL |
Cynthia A. Challener
Microbial identity data can be critical for determining contamination sources.
read more
| OUTSOURCING |
Susan Haigney
CMOs and CDMOs made investments in new and expanded facilities and services in the last quarter of 2018.
read more
| FROM THE EDITOR |
Rita C. Peters
Bio/pharma companies cannot spell success without solving all elements of quality programs.
read more
| US REGULATORY WATCH |
Jill Wechsler
Despite ongoing efforts to address the problem, FDA now sees a rise in active shortages and in the duration of supply problems.
read more
| ASK THE EXPERT |
Susan Schniepp
A required time frame should not be the driving force behind root cause investigations, says Susan Schniepp, executive vice-president of Post-Approval Pharma and Distinguished fellow, Regulatory Compliance Associates.
read more
|